Felbamate in epilepsy therapy. Evaluating the risks

Drug Safety

Volumn 21, Issue 3, 1999, Pages 225-239

  Pellock, John M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; AMITRIPTYLINE; AMOXAPINE; AMOXICILLIN; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLONAZEPAM; DIAZEPAM; EPOXIDE HYDROLASE; ERYTHROMYCIN; ESTROGEN; FELBAMATE; FREE RADICAL; HALOPERIDOL; IRON; LEVOTHYROXINE; LORAZEPAM; METOPROLOL; NADOLOL; NIFEDIPINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; SELENIUM; VALPROIC ACID; ZINC;

APLASTIC ANEMIA; BIOTRANSFORMATION; BLOOD CELL COUNT; BONE MARROW TOXICITY; CYTOPENIA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG SURVEILLANCE PROGRAM; DRUG TISSUE LEVEL; EPILEPSY; EPILEPTIC STATE; ERYTHROID CELL; HEPATITIS; HUMAN; IMMUNOPATHOLOGY; LIVER FAILURE; LIVER FUNCTION TEST; PRIORITY JOURNAL; REGISTER; REVIEW; RISK BENEFIT ANALYSIS;

ANIMALS; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; MALE; PROPYLENE GLYCOLS;

EID: 0032888645     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199921030-00006     Document Type: Review

References (85)

1. Bourgeois B, Leppik IE, Sackellares JC, et al. Felbamate: a double-blind efficacy trial following presurgical monitoring. Epilepsia 1991; 32: 18
2. Bourgeois B, Leppik IE, Sackellares JC, et al. Felbamate: a double blind, controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology 1993; 43: 693-6
3. Devinsky O, Faught RE, Wilder BJ, et al. Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures. Epilepsy Res 1995; 20: 241-6
4. Leppik IE, Dreifuss FE, Pledger GW, et al. Felbamate in partial seizures: results of Phase II clinical trial. Epilepsia 1989; 30: 661-2
5. Sachdeo RC, Kramer LD, Rosenberg A, et al. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992; 32: 386-93
6. Sachdeo RC, Kramer LD, Rosenberg A. Felbamate double-blind monotherapy trial. Ann Neurol 1991; 30: 290
7. Ritter FJ, Leppik IE, Dreifuss FF, et al. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox Gastaut Syndrome). N Engl J Med 1993; 328: 29-33
8. Leppik IE, Kramer LD, Bourgeois B, et al. Felbamate after withdrawal of other epileptic drugs [abstract]. Neurology 1990; 40: 158
9. Perhach JL, Weliky I, Newton JJ, et al. Felbamate. In: Meldrum BS, Porter RJ, editors. New anticonvulsant drugs. London-Paris: J Libbey, 1986: 117-23
10. Pellock JM, Brodie MJ. Felbamate; 1997 update. Epilepsia 1997; 38: 1261-4
11. DeGiorgio CM, Lopez JE, Lekht ZN, et al. Status epilepticus induced by felbatol withdrawal. Neurology 1995; 45: 1021-2
12. Lathers CM, Schraeder PL. Experience based teaching of therapeutics and clinical pharmacology of antiepileptic drugs: sudden unexplained death in epilepsy: do antiepileptic drugs have a role? J Clin Pharmacol 1995; 35: 573-87
13. Annegers JF, Coan SP, Hauser WA, et al. Epilepsy, vagal nerve stimulation by the NCP system, mortality and sudden, unexpected, unexplained death. Epilepsia 1998; 39: 206-12
14. Kaufman DW, Kelly JP, Anderson T, et al. Evaluation of the case reports of aplastic anemia among patients treated with felbamate. Epilepsia 1997; 38: 1265-9
15. Loui WS, Kang E, Cascino GD, Inwards DJ. Felbamate associated pancytopenia. Blood 1994: XX: 549
16. Pennel PB, Ogally MS, Macdonald RL. Aplastic anemia in a patient receiving felbamate for complex partial seizures. Neurology 1995; 45: 456-60
17. Ney GC, Schaul N, Loughlin J, et al. Thrombocytopenia in association with felbamate use. Neurology 1994; 44: 980-1
18. O'Neil MG, Perdun CS, Wilson MB, et al. Felbamate-associated fatal acute hepatic necrosis. Neurology 1996; 46: 1457-9
19. Watanable M, Iwashashi K, Kugoh T, et al. The relationship between phenytoin pharmacokinetics and CYP2C19 in Japane epileptic patients. Clin Neuropharmacol 1998; 21: 122-6
20. Chien JY, Peter RM, Nolan CM, et al. Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid. Clin Pharmacol Ther 1997; 61: 24-34
21. Kucharczyk N. Felbamate: chemistry and biotransformation. In: Levy RH, Mattson RH, Eldrum BS, editors. Antiepileptic drugs. New York: Raven Press Ltd, 1995; 799-806
22. 14C|-felbamate in healthy men. Epilepsia 1990; 21: 642
23. Kapetanovic IM, Torchin CD, Thompson CD, et al. A potentially reactive cyclic carbamate metabolite of the antiepileptic drug felbamate produced by human liver tissue in vitro. Drug Metab Dispos 1998; 26 (II): 1089-95
24. Sachdeo RC, Narang-Sachdeo SK, Shumaker RC, et al. Tolerability and pharmacokinetics of monotherapy felbamate doses of 1200-6000 mg/day in subjects with epilepsy. Epilepsia 1997; 38: 887-92
25. Sachdeo RC, Sachdeo S, Howard J, et al. Steady-state pharmacokinetics and dose proportionality of felbamate following oral administration of 1200, 2400 and 3600 mg/day felbamate [abstract]. Epilepsia 1993; 34: 80
26. Banfield CR, Zhu G-RR, Jen F, et al. The effect of age on apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling. Ther Drug Monit 1996; 18: 19-29
27. Yang JT, Morris M, Wong KK, et al. Felbamate metabolism in paediatric and adult beagle dogs. Drug Metab Dispos 1992; 20: 84-8
28. Data on File, Wallace Laboratories, 1999
29. Vincent PC. Drug-induced aplastic anemia and agranulocytosis: incidence and mechanisms. Drugs 1986; 31: 52-63
30. Thompson CD, Kinter MT, Macdonald TL. Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylprionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate. Chem Res Toxicol 1996; 9: 1225-9
31. Thompson CD, Gulden PH, Macdonald TL. Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. Chem Res Toxicol 1997; 10: 457-62
32. Glue P, Banfield CR, Perbach JL, et al. Pharmacokinetic interactions with felbamate: in vitro-in vivo correlation. Clin Pharmacokinet 1997; 33: 214-24
33. Levy, RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995; 36: S8-S13
34. Troupin AS, Montouris G, Hussein G. Felbamate: therapeutic range and other kinetic information. J Epilepsy 1997; 10: 26-31
35. Harden CL, Trifiletti R, Kutt H. Felbamate levels in patients with epilepsy. Epilepsia 1996; 37: 280-3
36. Racha JK, Mather GG, Bishop FE, et al. Involvement of CYP3A4 and CYP2E1 in the metabolism of felbamate in human liver microsomes. ISSX Proc 1996; 10: 370
37. Sachdeo RC, Narang Sachdeo SK, Montgomery PA, et al. Evaluation of the potential interaction between felbamate and erythromycin in patients with epilepsy. Clin Pharm Ther 1998; 38: 184-90
38. Banfield C, Saano V, Glue P, et al. Effects of felbamate on oral contraceptive pharmacokinetics. Clin Pharm Ther 1995; 57: 207-12
39. Albani F, Theodore WH, Washington P, et al. Effect of felbamate on plasma levels of carbamazepine and its metabolites. Epilepsia 1991; 32: 130-2
40. Holmes GB, Graves NM, Leppik IE, et al. Felbamate: bidrectional effects on phenytoin and carbamazepine serum concentrations. Epilepsia 1987; 28: 578-9
41. Fuerst RH, Graves NM, Leppik IE, et al. Felbamate increases phenytoin but decreases carbamazepine concentrations. Epilepsia 1988; 29: 488-91
42. Graves NM, Holmes GB, Fuerst RH, et al. Effect of felbamate on phenytoin and carbamazepine serum concentrations. Epilepsia 1989; 30: 225-9
43. Wagner ML, Graves NM, Marienau K, et al. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia 1991; 32: 398-406
44. Reidenberg P, Glue P, Banfield CR, et al. Effects of felbamate on pharmacokinetics of phenobarbital. Clin Pharmacol Ther 1995; 58: 279-87
45. Kelly JP, Jurgelon JM, Issargrisil S, et al. An epidemiological study of aplastic anaemia: relationship of drug exposures to clinical features and outcome. Eur J Hematol 1996; 37: 47-52
46. Gerson WT, Fine DG, Spielberg S, et al. Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood 1983; 61: 889-93
47. Pellock JM. Rational use of valproate in adults and children. In: Levy RH, Penry JK, editors. Idiosyncratic reactions to valproate: clinical risk patterns and mechanisms of toxicity. New York: Raven Press Ltd., 1991: 155-61
48. Pisciotta AV. Hemotologic toxicity of carbamazepine. In: Penry JK, Daily DD, editors. Advances in Neurology. Vol. II. New York: Raven Press, 1975: 355-68
49. Young NS. Pathophysiology II: immune suppression of haematopoiesis. In: Young NS, Alter BP, editors. Aplastic anemia acquired and inherited. Philadelphia: W.B. Saunders, 1994: 68-99
50. Young NS. Immune pathophysiology of acquired aplastic anemia. Eur J Hematol 1996; 57: 55-9
51. Yunis AA. Chloramphenicol toxicity In: Gridwood, editor. Blood disorders due to drugs and other agents. New York: Excerpta Medica, 1974: 107-26
52. De Wolff FA, Vermeij P, Ferrari MD, et al. Impairment of phenytoin parahydroxylation as a cause of severe intoxication. Ther Drug Monit 1983; 5: S213-5
53. Schattenberg DG, Stillman WS, Gruntmeir JJ, et al. Peroxidase activity in murine and human haematopoietic progenitor cells. Potential relevance to benzene-induced toxicity. Mol Pharmacol 1994; 46: 346-51
54. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest 1988; 182: 1826-32
55. Nagao T, Mauer AM. Concordance for drug-induced aplastic anemia in identical twins. N Engl J Med 1969; 281: 7-11
56. Loebstein R, Zahid N, Diev-Citrin O, et al. Deferiprone (L) induced agranulocytosis: a possible mechanism. Clin Pharmacol Ther 1997; 61: 139
57. Jimenez JJ, Armura GK, Abou-Khalil WH, et al. Chloramphenicol induced toxic bone marrow injury: possible role of bacterial metabolites of chloramphenicol. Blood 1987; 80: 1180-5
58. Spielberg SP, Gordon GB, Blake DA, et al. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981; 305: 722-7
59. Pichler WJ, Schnyder B, Zanni, MP, et al. Role of T cells in drug allergies. Allergy 1998; 53: 225-32
60. Moore MAS, Castro-Malaspina H. Immunosuppression in aplastic anemia - postponing the inevitable? N Engl J Med 1991; 324: 1358-60
61. Zimmerman HJ. Lesions of drug-induced liver disease and valproate hepatotoxicity. In: Levy RH, Penry JK, editors. Idiosyncratic reactions to valproate: clinical risk patterns and mechanisms of toxicity. New York: Raven Press, Ltd., 1991: 31-45
62. Griem P, Wulferink M, Sachs B, et al. Allergic and autoimmune reactions to xenobiotics: how do they arise? J Immunol 1998; 19: 133-41
63. Pohl LR, Pumford NR, Martin JL. Mechanisms, chemical structures and drug metabolism. Eur J Hematol 1996; 57: 98-104
64. Dreifuss FE, Langer DH, Moline KA, et al. Valproic acid hepatic fatalities: II: U.S. experience since 1984. Neurology 1989; 39: 201-7
65. Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987; 37: 379-85
66. Susman NM, McLain LW. A direct hepatotoxic effect of valproic acid. JAMA 1979; 242: 1173-4
67. Liu C-S, Wu HM, Kao SH, et al. Serum trace elements glutathione, copper/zinc superoxide dismutase, and lipid peroxidation in epileptic patients with phenytoin or carbamazepine monotherapy. Clin Neuropharmacol 1998; 21: 62-4
68. Pippenger CE. Update on epilepsy: approaches to prediction of idiosyncratic reactions antiepileptic drugs. J Clin Res Pharmacoepidemiol 1991; 5: 313-8
69. Thompson CD, Barthen MT, Hopper DW, et al. Quantification in patient urine samples of felbamate and three metabolites: acid carbamate and two mercapturic acids. Epilepsia 1999; 40: 769-76
70. Glauser TA, Titanic MK, Armstrong D, et al. Abnormalities in free radical scavenging enzyme activity in patients with felbamate-associated aplastic anemia. Epilepsia 1998; 39 Suppl. 2
71. Leeder SP. Influence of felbamate and its metabolites on cell viability. Epilepsia 1998; 39 Suppl. 6: 42
72. Uetrecht JP, Hahid N, Whitfield D. Metabolism of vesnarinone by activated neutrophils: implications for vesnarinone-induced agranulocytosis. J Pharmacol Exp Ther 1994; 24: 865-72
73. Uetrecht JP. Reactive metabolites and agranulocytosis. Eur J Hematol 1996; 57: 83-8
74. Uetrecht JP. The role of leucocyte-generated reactive metabolites in the pathhogenesis of idiosyncratic drug reactions. Drug Metab Rev 1992; 24: 299-366
75. Uetrecht JP. Evaluation of possible metabolic activation of felbamate by human neutrophils [abstract]. Epilepsia 1998; 39 Suppl. 6: 42
76. Gaedigk A, Spielberg SP, Grant DM. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 1994; 4: 142-55
77. Alter BP, Perhach JL. The effect of treatment with felbamate on erythropoiesis and erythroid progenitors in paediatric patients. Epilepsia 1998; 39 Suppl. 6: 163
78. Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992; 34: 377-95
79. Pellock JM, Willmore J. A rational guide to routine blood monitoring in patients receiving antiepileptic drugs. Neurology 1991; 41: 961-4
80. Hart RG, Easton JD. Carbamazepine and haematological monitoring. Ann Neurol 1982; 11: 309-12
81. Camfield P, Camfield C, Dooley J, et al. Routine screening of blood and urine for severe reactions to anticonvulsant drugs in asymptomatic patients is of doubtful value. Can Med Assoc J 1989; 140: 1303-5
82. Bryant AE, Dreifuss FE. Hepatotoxicity associated with antiepileptic drug therapy: avoidance, identification and management. CNS Drugs 1995; 4: 99-112
83. Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities: III: U.S. experience since 1986. Neurology 1995; 46: 465-9
84. Wyllie E, Wyllie R. Routine laboratory monitoring for serious adverse effects of antiepileptic medications: the controversy. Epilepsia 1991; 51: S74-9
85. Phillips BLB, Montouris-Gore MA, Montouris CD. Current use of felbamate in adult and paediatric populations with partial and generalized seizures. Epilepsia 1998; 39 Suppl. 6: 128